Natera Q2 revenue up 64% to $142M; guides FY2021 revenue to $600-620M

Natera, Inc.

2022-Q2 EPS reported -$2.06 revenue$294,342,000

Product revenue $137.2M, +70.7% YoY; processed 375,700 tests, +60.5%.
Net loss $116.0M ($1.32/share) vs $59.6M ($0.75) a year ago.
Raised 2021 revenue guidance to $600-620M from $550-575M (second increase).
Completed $551.2M net follow-on equity offering in July 2021.
CMS awarded ADLT status for Signatera MRD test; GSK phase III trial announced.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.